Key facts
- KÄÄPÄ Biotech’s last known valuation is $12.0M (Nov 2023).
- It has raised $17.9M; the latest was Later Stage VC ($10.4M) in Nov 2025.
- Notable investors include PeakBridge, Applied Food Sciences, HL Hall & Sons, Joyned Capital, Zintinus.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for KÄÄPÄ Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for KÄÄPÄ Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About KÄÄPÄ Biotech
Developer of a range of organic functional mushroom extracts designed to promote cognitive health and overall wellness. The company offers hand-harvested, sustainably sourced mushrooms, enabling health-conscious consumers to incorporate natural, bioactive compounds into their daily routines for enhanced vitality.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Karjalohja, Finland
- Founded
- 2018
- Employees
- 23
- Website
- kaapabiotech.com/
- Ownership
- Privately Held (backing)
KÄÄPÄ Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in KÄÄPÄ Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on KÄÄPÄ Biotech in its N-PORT filings yet. We sweep new filings monthly.